Candesartan Cilexetil in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM Preserved)

Conditions

Congestive Heart Failure

Keywords

Congestive Heart Failure, Atacand, Candesartan

Brief summary

A study to evaluate the effect of Atacand on patients with heart failure with preserved left ventricular function

Ostrominski JW, Højbjerg Lassen MC, Butt JH, Claggett BL, Anand IS, Desai AS, Jhund PS, Lam CSP, Pfeffer MA, Pitt B, Zannad F, Zile MR, Packer M, McMurray JJV, Solomon SD, Vaduganathan M.

2025-08-273 citations

10.1016/j.jacc.2025.08.012

Clinical Characteristics and Outcomes in Patients With Heart Failure: Are There Thresholds and Inflection Points in Left Ventricular Ejection Fraction and Thresholds Justifying a Clinical Classification?

Toru Kondo, Pooja Dewan, Inder S. Anand, Akshay S. Desai, Milton Packer et al. (13 authors)

Circulation2023-06-2739 citations

10.1161/circulationaha.122.063642

Investigator-reported ventricular arrhythmias and mortality in heart failure with mildly reduced or preserved ejection fraction

James P. Curtain, Carly Adamson, Toru Kondo, Jawad H. Butt, Akshay S. Desai et al. (18 authors)

European Heart Journal2023-01-1225 citations

10.1093/eurheartj/ehac801

Developing and validating models to predict sudden death and pump failure death in patients with heart failure and preserved ejection fraction.

Shen L, Jhund PS, Anand IS, Carson PE, Desai AS, Granger CB, Køber L, Komajda M, McKelvie RS, Pfeffer MA, Solomon SD, Swedberg K, Zile MR, McMurray JJV.

2020-12-1014 citations

10.1007/s00392-020-01786-8

Myocardial Infarction in Heart Failure With Preserved Ejection Fraction: Pooled Analysis of 3 Clinical Trials.

Cunningham JW, Vaduganathan M, Claggett BL, John JE, Desai AS, Lewis EF, Zile MR, Carson P, Jhund PS, Kober L, Pitt B, Shah SJ, Swedberg K, Anand IS, Yusuf S, McMurray JJV, Pfeffer MA, Solomon SD.

2020-05-0627 citations

10.1016/j.jchf.2020.02.007

Tromp J, Shen L, Jhund PS, Anand IS, Carson PE, Desai AS, Granger CB, Komajda M, McKelvie RS, Pfeffer MA, Solomon SD, Køber L, Swedberg K, Zile MR, Pitt B, Lam CSP, McMurray JJV.

2019-08-01124 citations

10.1016/j.jacc.2019.05.052

Heart Failure with Mid-Range Ejection Fraction in CHARM: Characteristics, Outcomes and Effect of Candesartan Across the Entire Ejection Fraction Spectrum

Lars H. Lund, Brian Claggett, Jiankang Liu, Carolyn S.P. Lam, Pardeep S. Jhund et al. (12 authors)

European Journal of Heart Failure2018-02-12418 citations

10.1002/ejhf.1149

Influence of Hospitalization for Cardiovascular Versus Noncardiovascular Reasons on Subsequent Mortality in Patients With Chronic Heart Failure Across the Spectrum of Ejection Fraction

Akshay S. Desai, Brian Claggett, Marc A. Pfeffer, Natalie A. Bello, Peter Finn et al. (11 authors)

Circulation Heart Failure2014-10-1860 citations

10.1161/circheartfailure.114.001567

Interventions

DRUGCandesartan

DRUGPlacebo

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

No

Inclusion criteria

* Male or female aged 18 or above * Congestive Heart Failure with symptoms for more than 4 weeks before starting study * Provision of informed consent

Exclusion criteria

* Current low blood pressure with symptoms * Liver disease considered significant by the study doctor * Pregnant or lactating females

Design outcomes

Primary

Measure	Time frame
Cardiovascular mortality or hospitalisation due to congestive heart failure	, 4, 6 weeks, 6 months, every 4 months thereafter until 24 months

Secondary

Measure	Time frame
Cardiovascular mortality or hospitalisation for management of congestive heart failure, or non fatal MI	Cardiovascular mortality or hospitalisation for management of congestive heart failure, or non fatal MI

Outcome results

None listed